Key PointsQuestionWhat is the effect of ivermectin on duration of symptoms in adults with mild COVID-19? FindingsIn this randomized clinical trial that included 476 patients, the duration of symptoms was not significantly different for patients who received a 5-day course of ivermectin compared with placebo (median time to resolution of symptoms, 10 vs 12 days; hazard ratio for resolution of symptoms, 1.07). MeaningThe findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand effects on other clinically relevant outcomes.
JAMA – American Medical Association
Published: Apr 13, 2021